Publication

Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment

Explore how ER upadacitinib formulations met 80–125% bioequivalence criteria under fasting and fed conditions using…

CertaraJune 1, 2026

Publication

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric-Coated Capsules in Healthy Chinese Subjects

Discover how high-fat meal reduces lansoprazole exposure by up to 61% in a bioequivalence study…

CertaraJune 1, 2026

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-BodnarMay 28, 2026

On-Demand Webinar

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…

CertaraMay 26, 2026

Blog

Certainty US 2026 recap: Advancing model-informed drug development right from the start

This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…

CertaraMay 26, 2026

Publication

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

CertaraMay 21, 2026

Poster

Quantitative Systems Pharmacology Modeling of Atopic Dermatitis to Predict Biologic Therapy Response

Explore a quantitative systems pharmacology (QSP) model of atopic dermatitis calibrated to clinical trial data.

CertaraMay 21, 2026

Publication

The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study

Learn how prospective study identifies AUC/MIC ≥ 9.90 as a PK/PD target for high-dose tigecycline…

CertaraMay 20, 2026

Guide

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…

CertaraMay 12, 2026

Poster

Predicting FcRn-Mediated PK/PD with PBPK Modeling

Learn how PBPK modeling predicts FcRn binder PK/PD and IgG dynamics across species.

CertaraMay 12, 2026

Modeling and Simulation

Comparative Pharmacokinetics of Two Extended-Release Tablet Formulations of Upadacitinib: Bioequivalence Assessment

Effect of High-Fat Meal on the Pharmacokinetics and Safety of Lansoprazole Enteric-Coated Capsules in Healthy Chinese Subjects

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators

Certainty US 2026 recap: Advancing model-informed drug development right from the start

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Quantitative Systems Pharmacology Modeling of Atopic Dermatitis to Predict Biologic Therapy Response

The pharmacokinetics/pharmacodynamics index of high-dose tigecycline in patients with carbapenem-resistant Enterobacterales bloodstream infection: a prospective study

How to Leverage PBPK Modeling and Simulation in Drug Research and Development

Predicting FcRn-Mediated PK/PD with PBPK Modeling

Newsletter sign up

Quick links

Solutions

Contact